home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

31.58 +0.35 (+1.12%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

March 06, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023

March 01, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology

February 28, 2023

From Edgewise Therapeutics

Via Business Wire

Recap: Edgewise Therapeutics Q2 Earnings ↗

August 04, 2022

Edgewise Therapeutics (NASDAQ:EWTX) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

RBC Capital Says This Dystrophy Stock 'Is Worth A Look' ↗

June 22, 2022

Via Benzinga

Edgewise's Dystrophy Candidate Lowers Muscle Damage Biomarkers ↗

June 21, 2022

Via Benzinga

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

February 23, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023

February 07, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

January 04, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023

December 21, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer

December 20, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at Upcoming Investor Conferences

November 09, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Reports Third Quarter 2022 Financial Results

November 03, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)

October 27, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

October 13, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society

October 06, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 16, 2022

From Edgewise Therapeutics, Inc.

Via Business Wire

Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday ↗

September 16, 2022

Gainers

Via Benzinga

Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

September 13, 2022

From Edgewise Therapeutics

Via Business Wire

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday ↗

September 14, 2022

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...

Via Benzinga

Edgewise Therapeutics Announces Proposed Offering of Common Stock

September 13, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

September 11, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)

September 07, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Reports Second Quarter 2022 Financial Results

August 04, 2022

From Edgewise Therapeutics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗

August 25, 2022

Upgrades

Via Benzinga

Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9

August 03, 2022

From Edgewise Therapeutics

Via Business Wire

6 Blue-Chip Stocks to Sell Now ↗

July 18, 2022

This article is about 6 blue-chip stocks to sell now. They are severely overvalued or are likely to move down soon with a recession.

Via InvestorPlace

Edgewise Therapeutics Initiates Mid-Stage Muscular Dystrophies Study ↗

July 12, 2022

Edgewise Therapeutics (NASDAQ: EWTX) announced the initiation of the CANYON Phase 2 clinical trial evaluating EDG-5506 in individuals with Becker Muscular Dystrophy (BMD).

Via Benzinga

Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)

July 12, 2022

From Edgewise Therapeutics

Via Business Wire

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗

June 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com